crmd_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 23, 2014

CORMEDIX INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
  
001-34673
  
20-5894890
(State or Other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
745 Rt. 202-206, Suite 303, Bridgewater, NJ
  
08807
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (908) 517-9500

 
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 5.07.
Submission of Matters to a Vote of Security Holders.

The Company’s 2014 annual meeting of stockholders was held on June 25, 2014.  At the meeting, stockholders elected the following seven members to the Company’s Board of Directors for a term expiring at the annual meeting of stockholders in 2015, based on the following votes:

Member
  
For
    
Withheld
    
Broker Non-Votes
  
Matthew Duffy
   10,831,938     2,966,983     0  
Michael W. George
   13,060,572     738,349     0  
Steven Lefkowitz
   13,632,077     166,844     0  
Taunia Markvicka
   13,796,066     2,855     0  
Randy Milby
   12,603,272     1,195,649     0  
Antony E. Pfaffle, M.D.
   13,653,317     145,604     0  
Cora M. Tellez
   13,060,572     738,349     0  
 
At the meeting, stockholders also ratified the appointment of Friedman LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.  The vote for such ratification was 13,765,181 shares for, 31,740 shares against, 2,000 shares abstaining and no broker non-votes.

Item 8.01.
Other Events.

On June 23, 2014, CorMedix issued a press release announcing that the protocol for a planned pivotal Phase 3 study for Neutrolin® for use in hemodialysis patients with a central venous catheter has been finalized.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits
 
Exhibit No.   Description
     
99.1   Press release dated June 23, 2014
 
 
2
 
                      
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

  CORMEDIX INC.  
       
Date: June 26, 2014      
By:
/s/ Randy Milby   
   
Name: Randy Milby
  
   
Title: Chief Executive Officer
  
       
                                             
 
 
3